Review on early technology assessments of nanotechnologies in oncology
Open Access
- 20 May 2009
- journal article
- review article
- Published by Wiley in Molecular Oncology
- Vol. 3 (5-6), 394-401
- https://doi.org/10.1016/j.molonc.2009.05.001
Abstract
Nanotechnology is expected to play an increasingly important role in the diagnostics, prognostics, and management of targeted cancer treatments. While papers have described promising results for nanotechnology in experimental settings, the translation of fundamental research into clinical applications has yet to be widely adopted. In future, policy makers will need to anticipate new developments for clinical implementation and introduce technology assessments. Here we present an overview of the literature on the technology assessments that have already been undertaken on early stage nanotechnology in cancer care, with particular emphasis placed on clinical efficacy, efficiency, logistics, patient‐related features and technology dynamics. Owing to the current stage of development of most nanotechnologies, we found only a limited number of publications describing the application of either Health Technology Assessment (HTA) or Constructive Technology Assessment (CTA). In spite of the promising conclusions of most papers concerning the benefits of clinical implementation, actual clinically relevant applications were rarely encountered, and so far only a few publications report application of systematic forms of technology assessment. Most articles consider aspects of environmental safety, regulation and ethics, often mentioning the need to investigate such issues more thoroughly. Evaluation of financial and organizational aspects is often missing. In order to obtain a realistic perspective on the translation and implementation process there is a need for a broad and systematic evaluation of nanotechnologies at early stages of development. Assessment methods taking technology dynamics into account, such as Constructive Technology Assessment (CTA) should be considered for evaluation purposes.Keywords
This publication has 47 references indexed in Scilit:
- Constructive Technology Assessment (CTA) as a tool in Coverage with Evidence Development: The case of the 70-gene prognosis signature for breast cancer diagnosticsInternational Journal of Technology Assessment in Health Care, 2009
- Innovations, challenges and future prospects of oncoproteomicsMolecular Oncology, 2008
- Application of Nanotechnology in Cancer Therapy and ImagingCA: A Cancer Journal for Clinicians, 2008
- Genome-wide association study identifies novel breast cancer susceptibility lociNature, 2007
- Methodology of constructive technology assessment in health careInternational Journal of Technology Assessment in Health Care, 2007
- Is Molecular Profiling Ready for Use in Clinical Decision Making?The Oncologist, 2007
- A common coding variant in CASP8 is associated with breast cancer riskNature Genetics, 2007
- Rapid and cost-effective polymorphism identification and genotyping using restriction site associated DNA (RAD) markersGenome Research, 2006
- Safe handling of nanotechnologyNature, 2006
- Near-infrared fluorescent type II quantum dots for sentinel lymph node mappingNature Biotechnology, 2003